*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.
asthma
Phase 2
No
-
All
265
Interventional
18 Years - 70 Years
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2016 by Takeda
Takeda
-
*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.
A phase 2, prospective double-blind, randomized parallel-group, multi-national, multi-center study with a single-blind baseline period in patients with mild to moderated bronchial asthma.
Location
Location
Hungary
Location
Spain
Location
Austria
Location
Poland
Location
Germany
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.